203
Views
4
CrossRef citations to date
0
Altmetric
Meta-analysis

The effect of inhaled corticosteroids on the outcomes of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, , ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 593-600 | Received 16 May 2022, Accepted 20 Jun 2022, Published online: 10 Jul 2022

References

  • WHO. https://covid19.who.int/ Accessed on 2022 Jun 7).
  • Lai CC, Chen IT, and Chao CM, et al. COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Rev Vaccines. 2021;20(8):1013–1025.
  • Shankar-Hari M, Vale CL, and Godolphin PJ, et al. Association between administration of il-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. Jama. 2021;326(6):499–518.
  • Sterne JAC, Murthy S, and Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. Jama. 2020;324(13):1330–1341.
  • Chen CY, Chen WC, Hsu CK, et al. Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: a systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2021;99:108027.
  • Lai CC, Chao CM, Hsueh PR. Clinical efficacy of antiviral agents against coronavirus disease 2019: a systematic review of randomized controlled trials. J Microbiol Immunol Infect. 2021;54(5):767–775.
  • Lai CC, Chen CH, Wang CY, et al. Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2021;76(8):1962–1968.
  • Kim SR, Song JH, Ahn JH, et al. Antiviral and anti-inflammatory activity of budesonide against human rhinovirus infection mediated via autophagy activation. Antiviral Res. 2018;151:87–96.
  • Peters MC, Sajuthi S, Deford P, et al. COVID-19-related genes in sputum cells in asthma. relationship to demographic features and corticosteroids. Am J Respir Crit Care Med. 2020;202(1):83–90.
  • Matsuyama S, Kawase M, Nao N, et al. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells. J Virol. 2020;95(1). DOI:10.1128/JVI.01648-20.
  • Finney LJ, Glanville N, Farne H, et al. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. J Allergy Clin Immunol. 2021;147(2):510–519.e515.
  • Milne S, Li X, Yang CX, et al. Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial. Eur Respir J. 2021;58(1):2100130.
  • Yu LM, Bafadhel M, and Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;398(10303):843–855.
  • Ramakrishnan S, Nicolau DV Jr., Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(7):763–772.
  • Bloom CI, Drake TM, Docherty AB, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021;9(7):699–711.
  • Ezer N, Belga S, Daneman N, et al. Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. BMJ. 2021;375:e068060.
  • Schultze A, Walker AJ, MacKenna B, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020;8(11):1106–1120.
  • Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(jul21 1):b2535.
  • Song JY, Yoon JG, Seo YB, et al. Ciclesonide inhaler treatment for mild-to-moderate COVID-19: a randomized, open-label, phase 2 trial. J Clin Med. 2021;10(16):3545.
  • Clemency BM, Varughese R, and Gonzalez-Rojas Y, et al. Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial. JAMA Intern Med. 2022;182(1):42-49.
  • Benfield T, Bodilsen J, and Brieghel C, et al. Improved survival among hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. A nationwide population-based cohort study. Clin Infect Dis. 2021;73(11):2031-2036.
  • Group RC, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693–704.
  • [cited 2021 Dec 27]. Available from: https://www.ema.europa.eu/en/news/insufficient-data-use-inhaled-corticosteroids-treat-covid-19
  • Lipworth B, Chan R, Misirovs R. High-dose budesonide for early COVID-19. Lancet. 2021;398(10317):2147.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.